UnitedHealth's Q1 Beat Changes The Turnaround Timeline

Revenue went from $287 billion in 2021 to $447 billion in 2025, a 12 percent compound annual growth rate. Net income told a different story: from $17.3 billion in 2021 up to $22.4 billion in 2023, then a drop to $14.4 billion in 2024 and $12.1 billion in 2025. The medical loss ratio moved adversely as pent-up procedure demand from the pandemic period collided with a Medicare Advantage rate cycle that did not fully reflect the cost pressure.

The story layered on top of the cost trend problem was the Change Healthcare cyberattack in 2024, which created reimbursement friction across the provider network and drove a temporary revenue recognition delay. The political overhang around pharmacy benefit managers and MA rates added a third layer. By mid-2025, the stock had corrected meaningfully from its peak, trading closer to a Utility-like 15x multiple.

The Q1 2026 beat is the first clean quarter since this sequence began. MLR normalised faster than consensus expected. Optum Health throughput improved. The company reaffirmed guidance with a constructive tone on the back half.

Three things change for the model. First, the medical cost trend appears to be peaking, not accelerating. The MLR move in Q1 is the kind of datapoint that lets the sell-side unwind conservatism on full-year earnings. Second, the Optum rehabilitation narrative regains credibility. Optum was supposed to be the secular growth engine that stabilised earnings through any Medicare Advantage headwind. That story had lost its shine in 2025. The Q1 print repairs it. Third, the multiple question resets. UnitedHealth had been trading at a steep discount to its five-year average multiple. A clean Q1 allows the rerate conversation to start.

The sector pattern here is instructive. When a managed care name normalises MLR after a multi-quarter spike, the consensus earnings revision cycle runs for three to four quarters. That creates a tailwind for the multiple even if the stock price has already moved. Humana went through the same pattern in 2016. Anthem had a similar sequence in 2018. The stocks compounded meaningfully through the normalisation window.

The signal is clearer when you look at operating income trajectory. Operating income peaked at $32.4 billion in 2023, held flat in 2024, then dropped to $19 billion in 2025. The Q1 2026 print implies the full-year operating income number is tracking closer to the $25 to $28 billion range than the bear case $20 to $22 billion range that was being modelled six months ago. That is the whole shift.

Elevance, Humana, Centene, CVS. Each has had its own MLR story over the last eighteen months. UnitedHealth arguably entered the cycle later than Humana and is emerging from it earlier than Elevance. At 18x forward earnings, the stock is priced between the Humana recovery multiple and the Elevance trough multiple.

The Optum advantage remains structural. No other managed care peer has a comparable provider services and pharmacy benefit manager combination at this scale. That is the moat that justified the multi-year premium multiple. The Q1 print is the first evidence that the moat still produces cash when the core insurance business stresses.

Against peers, UNH has the clearest runway to 2027 earnings growth. Consensus 2027 earnings are tracking toward $32 to $34 per share. At 18x forward, the fair value range works toward $600 to $615. The stock at $340 is pricing closer to $22 per share in earnings, which is overly cautious given the Q1 data.